Tag: ADC

Polatuzumab vedotin is a CD79b ADC for Large B-cell lymphomas (LBCL) Research

Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b for Large B-cell lymphomas (LBCL) Research.  CD79b is a surface antigen whose expression is restricted to pre‐B and mature B cells. Besides, CD79b is expressed on nearly all major subtypes of B-cell-derived NHL. While, Large B-cell lymphomas (LBCL) is a fast-growing...